The objective of this study is to identify prognosis and predictive markers of response to treatments (surgery, chemotherapy, targeted therapy,loco-regional treatments ) in patients with bile duct cancer. The effectiveness and tolerance of these treatments in current practice will also be evaluated.
All locations of primitives (intrahepatic CCA, extrahepatic CCA, adenocarcinoma of the gallbladder; ampullomas excluded)
Age > 18 years
Diagnosed between 2003 and 2030 (minimum follow-up 2 years)
Patient under guardianship, curatorship or legal protection
Pregnant or breastfeeding women
Any medical, psychological or social situation, which could prevent the compliance with the protocol according to the investigator's assessment
Refusal to participate in the study